Precision Medicine Group, LLC Sustainability Profile
Precision Medicine Group, LLC, headquartered in the United States, is a leading entity in the life sciences industry, specialising in precision medicine and drug development. Founded in 2014, the company has rapidly established itself as a key player, offering a comprehensive suite of services that includes clinical trial management, regulatory consulting, and market access strategies. With a focus on personalised healthcare solutions, Precision Medicine Group leverages advanced analytics and innovative methodologies to enhance patient outcomes. Their unique approach integrates scientific expertise with operational excellence, setting them apart in a competitive market. The company has achieved significant milestones, including collaborations with major pharmaceutical firms and contributions to groundbreaking therapies, solidifying its reputation as a trusted partner in the evolving landscape of healthcare.
DitchCarbon Score
How does Precision Medicine Group, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Precision Medicine Group, LLC's score of 25 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Precision Medicine Group, LLC's reported carbon emissions
Precision Medicine Group, LLC, headquartered in the United States, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is committed to climate action, having established near-term targets as part of its sustainability initiatives. While no net-zero commitment has been made, Precision Medicine Group is actively engaged in reducing its carbon footprint within the pharmaceuticals, biotechnology, and life sciences sector. The company has committed to near-term targets, although specific reduction goals or timelines have not been disclosed. It is important to note that Precision Medicine Group, LLC is a current subsidiary, and any relevant emissions data or climate commitments may be cascaded from its parent organisation. The company is aligned with industry standards and practices, reflecting a growing trend among corporations to address climate change proactively. As the company continues to develop its climate strategy, stakeholders can expect further details on its emissions and reduction initiatives in the future.
How Carbon Intensive is Precision Medicine Group, LLC's Industry?
How Carbon Intensive is Precision Medicine Group, LLC's Location?
Precision Medicine Group, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Precision Medicine Group, LLC has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
